COVID 19-Caregivers IGg Seroconversion (CoSigS)
Comparison of the Proportion of Covid19 Seroconversion of Caregivers Working or Not in the COVID Sector
According to recent publications, the percentage of caregivers infected with COVID 19 is evaluated between 10 and 30% . This great variability is due, on the one hand to the intensity of the influx of covid plus patients and, on the other hand, to the disparity in the preparation of caregivers in the face of this emergency. Indeed, we can understand that the strict application of hygiene rules can be faulted in the face of the volume of patients, the lack of protective equipment and the lack of specific training for caregivers in this area. As a result, within healthcare teams, there are many questions that generate anxiety: will I be able to provide care properly while protecting myself from the risk of contamination? This anxiety is also present and sometimes manifests itself aggressively in the entourage or in the vicinity of caregivers, due to lack of scientific data adapted to the local ecology of the crisis.
Thus, the aim of this study is to show that the risk for caregivers of being contaminated by COVID in an area dedicated to COVID positive patients is no higher than being a caregiver in a non-COVID area that he either in the adult or pediatric sector.
調査の概要
研究の種類
連絡先と場所
研究場所
-
-
-
Limoges、フランス
- chu de Limoges
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
サンプリング方法
調査対象母集団
Caregivers staff assigned to a non-intensive care COVID service
- Or caregiversg staff assigned to a non-COVID adult service
- Or caregivers staff assigned to a non-COVID pediatric service
説明
Inclusion Criteria:
- caregivers staff assigned to a non-intensive care COVID service
- or caregivers staff assigned to a non-COVID adult service
- or caregivers staff assigned to a non-COVID pediatric service
- Age > = 18 years old
- With health insurance
- Express consent
Exclusion Criteria:
- Protected persons
- Refusal to participate
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
介入・治療 |
|---|---|
|
Covid area
|
3 blood samples (D0, D15 and D30) will be taken from each participant
|
|
Non-Covid area
|
3 blood samples (D0, D15 and D30) will be taken from each participant
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Seroconversion
時間枠:Day1
|
Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation.
|
Day1
|
|
Seroconversion
時間枠:Day 15
|
Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation.
|
Day 15
|
|
Seroconversion
時間枠:Day 30
|
Participants seroconverion will be assessed by analysing IgG When the seroconverion is confirmed (whenever it occurs), the participant ends his partipation.
|
Day 30
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- 87RI20_0016/CoSigS
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。